MaxCyte will acquire Akron Bio for $151.8 million, utilizing a mix of cash, stock, and a new $75.0 million credit facility to expand its cell therapy manufacturing footprint and reach profitability.
MaxCyte announced a definitive $151.8 million acquisition of Akron Bio (expected to close before end of 2026), which is expected to nearly double MaxCyte's revenue base. Akron brings ~$28 million in 2026 revenue and $7-8 million EBITDA, cutting the combined company's 2027 cash burn to less than $10 million and accelerating the path to profitability. The deal includes $105.0 million cash, ~$26.8 million in new shares, $20.0 million deferred payments, and a new up-to-$75.0 million MidCap credit facility, funded through profitability with $40-45 million cash expected at closing.
MaxCyte, Inc. has entered a definitive agreement to acquire Akron Bio for $151.8 million in a deal expected to close by the end of 2026. The acquisition is projected to nearly double MaxCyte's revenue base and accelerate its path to profitability by integrating Akron's $28 million in 2026 revenue and $7-8 million in EBITDA.
MaxCyte is acquiring Akron Bio from affiliates of Arcline Investment Management for $151.8 million total consideration: $105.0 million cash at closing, about $26.8 million in MaxCyte stock (20,639,733 shares), and $20.0 million in deferred payments due in January 2028 and January 2029.
Akron is expected to add roughly $28 million in revenue and $7-8 million in EBITDA in 2026, nearly doubling MaxCyte's revenue base, cutting 2027 cash burn to less than $10 million, and accelerating the path to profitability with $40-45 million in cash expected at closing plus up to $75.0 million in credit availability.